Post-Coronavirus Disease 2019 (COVID-19) Antibody levels in End-Stage Renal Disease (ESRD) patients

• Conditions: End-stage renal disease patients with renal replacement therapy recovered from COVID-19; ESRD; End stage kidney disease; COVID-19; SARS-CoV-2; Post COVID-19; RRT; Renal replacement therapy

• Registration Number: TCTR20211005004
• Lead Sponsor: Bamrasnaradura Infectious Diseases Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-05
• Study Completion: 2022-05-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Age 18 years or more
2. End stage renal disease patient
3. Recovered from COVID-19 in Bamrasnaradura Infectious Diseases Institute
4. Informed consent for participation

Exclusion Criteria

1. Develop end stage renal disease after COVID-19
2. Received any COVID-19 vaccination

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 Antibody 0, 1, 3, 6 months after recovered from COVID-19 ELISA

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A